Why Order Pancreatic Enzyme Replacement Therapy (PERT)
You order pancreatic enzyme replacement therapy when a patient has exocrine pancreatic insufficiency (EPI), which causes maldigestion of nutrients—particularly fats—leading to malnutrition, fat-soluble vitamin deficiencies, and reduced quality of life and survival if left untreated. 1
High-Risk Conditions Requiring PERT
PERT should be strongly suspected and ordered in patients with:
- Chronic pancreatitis (most common indication)
- Relapsing acute pancreatitis
- Pancreatic ductal adenocarcinoma (associated with reduced survival and quality of life when EPI is untreated)
- Cystic fibrosis
- Previous pancreatic surgery (including pancreatoduodenectomy) 1
These high-risk conditions directly damage or remove pancreatic tissue, reducing enzyme secretion below the critical threshold of 10% of normal function needed for adequate fat digestion. 2
Moderate-Risk Conditions to Consider
PERT should also be considered in:
- Duodenal diseases (celiac disease, Crohn's disease)
- Previous intestinal surgery
- Longstanding diabetes mellitus
- Hypersecretory states (Zollinger-Ellison syndrome) 1
Clinical Presentation Triggering PERT
Order PERT when patients present with:
- Steatorrhea (with or without diarrhea)
- Unintentional weight loss
- Bloating and excessive flatulence
- Fat-soluble vitamin deficiencies (A, D, E, K)
- Protein-calorie malnutrition
- Sarcopenia despite normal or elevated BMI 1
Diagnostic Confirmation
Before ordering PERT, confirm EPI with:
- Fecal elastase-1 test (most appropriate initial test)
- <100 mg/g stool = definite EPI
- 100-200 mg/g = indeterminate
- Must be performed on semi-solid or solid stool 1
Important caveat: Do NOT rely on a therapeutic trial of pancreatic enzymes for diagnosis—this approach is unreliable. 1 Imaging (CT, MRI, EUS) cannot identify EPI, though they help diagnose underlying pancreatic disease. 1
Why Treatment is Mandatory
Once EPI is diagnosed, PERT is required—not optional. 1 Untreated EPI results in:
- Progressive malnutrition
- Fat-soluble vitamin deficiencies leading to osteopathy and fractures
- Reduced quality of life
- Increased mortality (particularly in pancreatic cancer patients) 1
- Reduced tolerance to oncologic therapy in cancer patients 1
The evidence is clear that PERT significantly improves both fat absorption (CFA) and protein absorption (CNA) across all major etiologies of EPI, with particularly strong effects in cystic fibrosis (SMD = 1.87) and chronic pancreatitis (SMD = 1.08). 3
Prescribing Approach
When ordering PERT:
- Start with 40,000 USP units of lipase with each meal and 20,000 units with snacks in adults 1
- All FDA-approved formulations (Creon, Zenpep, Pancreaze, Pertzye) are equally effective at equivalent doses 1
- Enteric-coated preparations are preferred (do not require acid suppression)
- Non-enteric-coated formulations (Viokace) require concurrent PPI or H2-blocker 1
Critical point: PERT treats the meal, not the pancreas—it must be taken during meals to maximize mixing with food. 1
Monitoring Treatment Success
Order PERT with the expectation of monitoring:
- Reduction in steatorrhea and GI symptoms
- Weight gain and improved muscle mass/function
- Improvement in fat-soluble vitamin levels
- Baseline and annual fat-soluble vitamin levels
- DEXA scan at baseline and every 1-2 years 1
Common Pitfall to Avoid
Do not prescribe over-the-counter pancreatic enzyme supplements—they are unregulated dietary supplements with unknown efficacy and safety. Only FDA-approved PERT formulations should be ordered. 1
The cost of PERT is a significant barrier to therapy, particularly in patients without adequate insurance coverage, which may require working with manufacturer patient-assistance programs. 1, 4